Chembio Diagnostics (CEMI) – StreetInsider.com Reports
-
Chembio Diagnostics' (CEMI) CEO Letter to Stockholders
-
Chembio Diagnostics (CEMI) Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System
-
Chembio Diagnostics (CEMI) Acquired by Biosynex for $0.45/sh
-
Chembio Diagnostics (CEMI) Halted, News Pending
-
Chembio Diagnostics (CEMI) Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System
-
Chembio Diagnostics (CEMI) Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay
-
Chembio Diagnostics (CEMI) awarded a $3.25m CDC contract
-
Chembio Diagnostics (CEMI) on Watch on Department of Agriculture News
-
Chembio Diagnostics (CEMI) Appoints Leslie Teso-Lichtman to its Board
-
Chembio Diagnostics (CEMI) Appoints Larry Steenvoorden as CFO
-
Chembio Diagnostics (CEMI) Submits FDA De Novo/510(k) Request for DPP SARS-CoV-2 Antigen Test System
-
Pre-Open Stock Movers 11/17: (AVGR) (RMTI) (VRAR) Higher; (SAVA) (AVIR) (STNE) Lower (more...)
-
After-Hours Stock Movers 11/16: (CEMI) (LZB) (VREX) Higher; (AVIR) (STNE) (DLB) Lower (more...)
-
Chembio Diagnostics (CEMI) Submits EUA Application for New DPP SARS-CoV-2 Antigen Test
-
Chembio Diagnostics (CEMI) Announces EUA Submission for DPP Respiratory Antigen Panel
-
Increasing unusual call option volume: EWJ CEMI ATER HP SLQT BBIG
-
Increasing unusual call option volume: CEMI OPRX SLQT WDAY BILL SOAC
-
Chembio Diagnostics (CEMI) Announces Commercial Distribution of Third-Party COVID-19 Antigen Assay
-
Chembio Diagnostics (CEMI) Gains Said Tied to EUA for Partner
-
Colliers Securities Downgrades Chembio Diagnostics (CEMI) to Hold
-
Pre-Open Stock Movers 07/21: (CEMI) (LE) (SDC) Higher; (SNBR) (FOUR) (MGTA) Lower (more...)
-
Chembio Diagnostics (CEMI) Announces $28.3M Order for DPP SARS-CoV-2 Antigen Tests in Brazil
-
Chembio Diagnostics (CEMI) Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu (earlier)
-
Chembio Diagnostics (CEMI) Announces David Bespalko to Board
-
Craig-Hallum Upgrades Chembio Diagnostics (CEMI) to Buy
-
Chembio Diagnostics (CEMI) Awarded $12.7 Million by BARDA for Rapid DPP SARS-CoV-2 Antigen Test System
-
Colliers Securities Upgrades Chembio Diagnostics (CEMI) to Buy
-
Chembio Diagnostics (CEMI) Receives FDA Approval for DPP HIV-Syphilis System
-
Chembio Diagnostics (CEMI) partner LumiraDX gets FDA Emergency Use Authorization for its LumiraDx SARS-CoV-2 RNA STAR test
-
Chembio Diagnostics (CEMI) sees Q2 revenue of $4.5 million to $4.7 million
-
Chembio Diagnostics (CEMI) Awarded BARDA Contract for Development of DPP COVID-19 Point-of-Care Antigen System
-
Chembio Diagnostics (CEMI) to Seek EUA Approval from FDA for Revised DPP COVID-19 IgM/IgG System and New DPP COVID-19 Antigen System
-
Chembio Diagnostics (CEMI) awarded a $628K HHS contract for research and development of a SARS-COV-2 AG System
-
Chembio Diagnostics (CEMI) Cut in Half After FDA Revokes EUA for its COVID-19 Serological Test Due to 'Performance Concerns'
-
Pre-Open Movers 06/17: (WATT) (INWK) (GRPN) Higher; (CEMI) (ATNM) (NCLH) Lower (more...)
-
Baird Downgrades Chembio Diagnostics (CEMI) to Neutral
-
Chembio Diagnostics (CEMI) PT Lowered to $8 at Craig-Hallum
-
Colliers Securities Downgrades Chembio Diagnostics (CEMI) to Hold
-
Craig-Hallum Downgrades Chembio Diagnostics (CEMI) to Hold
-
Benchmark Downgrades Chembio Diagnostics (CEMI) to Hold
-
Canaccord Genuity Downgrades Chembio Diagnostics (CEMI) to Hold as FDA Revoked EUA
-
Chembio Diagnostics (CEMI) Receives FDA 510(k) Clearance for DPP Zika IgM System
-
Baird Starts Chembio Diagnostics (CEMI) at Outperform
-
Chembio Diagnostics (CEMI) PT Raised to $22 at Canaccord Genuity
-
Chembio Diagnostics (CEMI) Announces US Distribution Agreement to Expand Reach of DPP COVID-19 Serological Test with Thermo Fisher Scientific’s Healthcare Channel
-
Chembio Diagnostics (CEMI) Prices 2.34M Common Stock Offering at $11.75/sh
-
Chembio Diagnostics (CEMI) to Offer Common Stock
-
Chembio Diagnostics (CEMI) PT Raised to $21 at Craig-Hallum
-
Chembio Diagnostics (CEMI) Ramps Following FDA Approval for Point-of-Care COVID-19 Test
-
Chembio Diagnostics (CEMI) PT Raised to $12 at Canaccord Genuity
Back to CEMI Stock Lookup